Neuralstem (CUR) Surpasses 50% Enrollment Mark in Phase 2 MDD Study
Tweet Send to a Friend
Neuralstem, Inc. (Nasdaq: CUR) announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
